

FLI1 (D7N5M) Rabbit mAb



Orders: 877-616-CELL (2355)

orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com

cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

W, IP	Reactivity: H M	Sensitivity: Endogenous	MW (kDa): 52	Source/Isotype: Rabbit IgG	UniProt ID: #Q01543	Entrez-Gene Id 2313
Product Usage Information		Application Western Blotting Immunoprecipitation			Dilution 1:1000 1:50	
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μ g/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.				
Specificity/Sensitivity		FLI1 (D7N5M) Rabbit mAb recognizes endogenous levels of total FLI1 protein.				
Species predicted to react based on 100% sequence homology		Rat, Zebrafish				
Source / Purification		Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val64 of human FLI1 protein.				
Background		Friend leukemia integration 1 (FLI1) transcription factor is an ETS domain-containing transcription factor that plays an important and highly conserved role in vertebrate development, particularly hematopoiesis, where it functions to activate transcription of genes that promote erythroblast proliferation (1-4). In mice, the <i>Fli1</i> locus is a common retroviral insertion site for the Friend murine leukemia virus (F-MuLV), such that a majority of F-MuLV-induced erythroleukemias are associated with aberrant Fli1 expression (5). Notably in humans, aberrant FLI1 expression has also been linked to poor prognosis in acute myeloid leukemia (6). Also in humans, a t(11;22)(q24;q12) chromosomal translocation has been described that generates a chimeric protein (EWS/FLI1) comprised of the aminoterminal transactivation domain of Ewing's sarcoma breakpoint region 1 (EWS) and the carboxyterminal ETS domain of FLI1 (7). The EWS/FLI1 fusion protein functions as a transcriptional activator that is reportedly responsible for >85% of the known cases of pediatric Ewing's sarcoma, an aggressive bone and soft tissue tumor (8,9).				
		leukemia virus (F-MuL' aberrant Fli1 expression prognosis in acute my translocation has been terminal transactivation terminal ETS domain of that is reportedly resp	v), such that a majo on (5). Notably in ho eloid leukemia (6). In described that ge on domain of Ewing of FLI1 (7). The EWS onsible for >85% o	ority of F-MuLV-induced umans, aberrant FLI1 ex Also in humans, a t(11;2 nerates a chimeric prote i's sarcoma breakpoint r /FLI1 fusion protein fun	erythroleukemias a pression has also b 2)(q24;q12) chromo ein (EWS/FLI1) comp egion 1 (EWS) and t ctions as a transcrip	ire associated with een linked to poor osomal orised of the amino- the carboxy- otional activator

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

W: Western Blotting **IP:** Immunoprecipitation

Cross-Reactivity Key

H: Human M: Mouse

Trademarks and Patents

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

XP is a registered trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party. whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.